CULLINAN THERAPEUTICS, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- CULLINAN THERAPEUTICS, INC. payments for repurchase of common stock for the quarter ending 2020-12-31 was $6.36M.
- CULLINAN THERAPEUTICS, INC. payments for repurchase of common stock for the quarter ending 2020-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. payments for repurchase of common stock for the quarter ending 2020-06-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. payments for repurchase of common stock for the quarter ending 2020-03-31 was $213.00K.
- CULLINAN THERAPEUTICS, INC. payments for repurchase of common stock for fiscal 2020 was $6.57M.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2020-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $6.57M 10-K · filed 2022-03-17 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | |
| 2020-03-31 | $213.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |